BR112013000788A2 - formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida - Google Patents

formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida

Info

Publication number
BR112013000788A2
BR112013000788A2 BR112013000788A BR112013000788A BR112013000788A2 BR 112013000788 A2 BR112013000788 A2 BR 112013000788A2 BR 112013000788 A BR112013000788 A BR 112013000788A BR 112013000788 A BR112013000788 A BR 112013000788A BR 112013000788 A2 BR112013000788 A2 BR 112013000788A2
Authority
BR
Brazil
Prior art keywords
methyl
difluorophenyl
thio
oxy
crystalline forms
Prior art date
Application number
BR112013000788A
Other languages
English (en)
Inventor
Anne Ingela Gullberg Britt
Paul Stonehouse Jeffrey
Thomas Larsson Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112013000788A2 publication Critical patent/BR112013000788A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida. a presente invenção refere-se a formas cristalinas de 5-anidrato de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidinil]-4-azetidino sulfonamida. tais compostos / formas podem ser úteis no tratamento de uma doença / condição na qual a modulação de atividade de receptor de quimiocina é benéfica.
BR112013000788A 2010-07-13 2011-07-12 formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida BR112013000788A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36372610P 2010-07-13 2010-07-13
PCT/GB2011/051308 WO2012007748A1 (en) 2010-07-13 2011-07-12 New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide

Publications (1)

Publication Number Publication Date
BR112013000788A2 true BR112013000788A2 (pt) 2017-09-26

Family

ID=44358090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000788A BR112013000788A2 (pt) 2010-07-13 2011-07-12 formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida

Country Status (16)

Country Link
US (2) US8748603B2 (pt)
EP (1) EP2593448A1 (pt)
JP (1) JP2013531027A (pt)
KR (1) KR20130103483A (pt)
CN (1) CN103097377A (pt)
AR (1) AR084705A1 (pt)
AU (1) AU2011278115B2 (pt)
BR (1) BR112013000788A2 (pt)
CA (1) CA2804162A1 (pt)
MX (1) MX2013000289A (pt)
MY (1) MY167869A (pt)
RU (1) RU2548044C2 (pt)
SG (1) SG186859A1 (pt)
TW (1) TWI496773B (pt)
UY (1) UY33506A (pt)
WO (1) WO2012007748A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262286A (ja) * 1985-09-13 1987-03-18 株式会社東芝 沸騰水型原子炉炉心
RU2548044C2 (ru) * 2010-07-13 2015-04-10 Астразенека Аб Новые кристаллические формы n-[-2[[(2,3-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азетидин-сульфонамида
MY180039A (en) 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
EP2740458B1 (en) * 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
CN103113333B (zh) * 2012-12-20 2015-07-08 浙江普洛康裕制药有限公司 一种维生素c乙基醚的合成方法
WO2016079049A1 (en) * 2014-11-17 2016-05-26 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
BR112018068393A2 (pt) 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083567C1 (ru) * 1991-04-25 1997-07-10 Ф.Хоффманн-Ля Рош Аг Производные арилсульфонамида или их соли и фармацевтическая композиция, проявляющая ангиопротекторное, антигипертензивное и вазоспазмолитическое, в частности противоишемическое, действие
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
RS53145B (en) 2004-08-28 2014-06-30 Astrazeneca Ab. PIRIMIDINE SULFONAMIDE DERIVATIVES AS CHEMOKIN RECEPTOR MODULATORS
KR20110031462A (ko) 2008-07-16 2011-03-28 아스트라제네카 아베 피리미딜 술폰아미드 유도체 및 케모카인 매개 질환의 치료를 위한 그의 용도
JP2011529027A (ja) 2008-07-25 2011-12-01 ビーエーエスエフ ソシエタス・ヨーロピア ３−アミノメチル−１−シクロヘキシルアミン、及びその製造方法
RU2548044C2 (ru) * 2010-07-13 2015-04-10 Астразенека Аб Новые кристаллические формы n-[-2[[(2,3-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азетидин-сульфонамида
MY180039A (en) 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator

Also Published As

Publication number Publication date
KR20130103483A (ko) 2013-09-23
AU2011278115B2 (en) 2014-11-06
MX2013000289A (es) 2013-03-08
RU2013103754A (ru) 2014-08-20
US8748603B2 (en) 2014-06-10
TW201209041A (en) 2012-03-01
RU2548044C2 (ru) 2015-04-10
US20120015927A1 (en) 2012-01-19
SG186859A1 (en) 2013-02-28
TWI496773B (zh) 2015-08-21
CN103097377A (zh) 2013-05-08
AU2011278115A1 (en) 2013-01-24
WO2012007748A1 (en) 2012-01-19
MY167869A (en) 2018-09-26
EP2593448A1 (en) 2013-05-22
AR084705A1 (es) 2013-06-05
CA2804162A1 (en) 2012-01-19
UY33506A (es) 2012-02-29
US20140235606A1 (en) 2014-08-21
JP2013531027A (ja) 2013-08-01

Similar Documents

Publication Publication Date Title
BR112013000788A2 (pt) formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida
EA201500574A1 (ru) Новые инданилоксидигидробензофуранилуксусные кислоты
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
EA201391639A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EA201290310A1 (ru) Производные имидазолидиндиона
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
EA201301320A1 (ru) 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
PE20142148A1 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
RS54205B1 (en) L-PROLINE AND CO-CRYSTALS OF LUMIC ACID OF (2S, 3R, 4R, 5S, 6R) -2- (3 ((5- (4-FLUOROPHENYL) THIOPHEN-2-IL) METHYL-4-METHYLPHENYL) -6- (HYDROXYMETHYL) TETRAHYDRO-2H-PYRAN-3, 4, 5-TRIOLA
EA201290121A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
UA116809C2 (uk) Застосування агрохімічних сумішей для збільшення життєздатності рослини
EA200970173A1 (ru) Химические соединения
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
EA201590562A1 (ru) Бензамиды
BR112012017994A2 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
EA201690972A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
EA201170481A1 (ru) Сокристаллы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL